Journal
CANCER TREATMENT REVIEWS
Volume 60, Issue -, Pages 109-119Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2017.08.006
Keywords
Colorectal cancer; BRAF; Targeted therapy
Categories
Funding
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes. (c) 2017 The Author(s). Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available